NL-OMON24147已完成不适用
Transfusion Effects of Myelodysplastic Patients: Limiting Exposure.
Sanquin Blood Bank South West RegionSanquin Blood Bank South West RegionWytemaweg 103015 CN RotterdamThe NetherlandsTel: 0031 10-4630630Fax: 0031 10-4630640E-mail: dick.van.rhenen@bloodrtd.nl0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
British Journal of Haematology 2003;121(2):270-274
NVB Bulletin oktober 2002;3:2-5
Nederlands Tijdschrift voor Klinische Chemie 2003; 28: 280-284.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Diagnosis myelodysplastic syndrome (primary or secondary) based on cytopenia in at least 1 cell line + dysplasia in 2 cell lines (and no other cause (especially deficiencies)) and a pathologic anatomic diagnosis after bone marrow punction;
- •2. Refractory anaemia (RA): blood: ¡Ü 1% blasts, ¡Ü 1 x 109 monocytes; bone marrow: < 5% blasts, ringed sideroblasts ¡Ü 15% of the erythroid cells;
排除标准
- •1. Candidate for bone marrow- or organ transplantation;
- •2. Medication: growth factors (GM-CSF), or EPO;
研究者
相似试验
已完成
不适用
Transfusion Effects of Myelodysplastic Patients: Limiting ExposureMyelodysplastic Syndrome (MDS)Myelodysplastic SyndromeCancerISRCTN43616311Sanquin Blood Bank South West Region (The Netherlands)200
已完成
不适用
Transfusion use in patients with rare blood cancer (myelodysplastic syndromes)Myelodysplastic syndromesCancerISRCTN38059137Karolinska Institute2,858
撤回
4 期
Transfusion Effects in Myelodysplastic Patients: Limiting ExposureMyelodysplastic SyndromesNCT00202371Sanquin Research & Blood Bank Divisions
Unknown
2 期
Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive ChemotherapyMyelodysplastic SyndromeNCT01356875Basque Health Service42
招募中
2 期
Repurposed Drugs to Improve Haematological Responses in Myelodysplastic SyndromesMyelodysplastic Syndromes (MDS)NCT04997811Prof. Janet Dunn120